Therapeutic Drug Monitoring and Population Pharmacokinetics of Digoxin in Jordanian Patients

Ehab Shaker, Salim Hamadi, Nasir Idkaidek^, , Graham E Blakey and Akram Al-Saleh

Cite this paper:
Ehab Shaker, Salim Hamadi, Nasir Idkaidek, Graham E Blakey and Akram Al-Saleh. Therapeutic Drug Monitoring and Population Pharmacokinetics of Digoxin in Jordanian Patients. American Journal of Pharmacological Sciences. 2013; 1(2):15-21. doi: 10.12691/ajps-1-2-1

Abstract

Therapeutic monitoring of digoxin and the population pharmacokinetic parameters in Jordanian patients were done. Fifty three patients visited cardiac department of Jordan University hospital participated in this study, thirty two patients had congestive heart failure (CHF), while twenty one patients had atrial fibrillation (AF). Ninety three blood samples were collected from those patients for the measurement of digoxin level using AxSYM digoxin II assay method. Serum creatinine and potassium levels were also measured, in addition to blood pressure and heart rate. Microsoft Excel and Statistica programs were used for kinetic and statistical analysis. NONMEM computer program ADVAN 4 and 2 compartment model was used for population analysis of digoxin parameters. The serum digoxin level ranged from 0.11-4 ng/ml. The percentage of all patients enrolled in this study that were out of therapeutic range was 49.05%. Serum digoxin levels were out of therapeutic range in 53.12% of patients with CHF and 42.85% in those with AF. The pharmacokinetic parameters for digoxin obtained in this study using traditional methods were: creatinine clearance CLcr (89.78 ± 45.61 ml/min), digoxin actual clearance CL (200.57 ± 154.52 L/day), volume of distribution V (541.57 ± 149.87L), t1/2(2.98 ± 2.05 day), elimination rate constant (0.41± 0.396 day-1). A strong correlation was also found between actual digoxin clearance with log dose normalized (R2=0.999), and t1/2 (R2= 0.875). No correlations were found between the log of the normalized dose and other pharmacokinetic parameters or potassium levels. The population pharmacokinetic parameter for digoxin obtained in this study were: CL (3.34L/h), Vc (3.27L), Vt (123L), inter-compartment clearance Q (72L/h), absorption rate constant KA (1.25h^-1). In Jordanian patients with either AF or CHF digoxin dose adjustment based on therapeutic drug monitoring principles is recommended. Digoxin pharmacokinetics were similar to those reported in non-Jordanian patients; estimated population pharmacokinetic parameters were in agreement with literature values.

Keywords:
digoxin population pharmacokinetics TDM NONMEM

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Figueiredo, E.L., Machado, F.P. Digoxin's roles in heart failure patients: An overview. Cardiology. 5 (5): 59-64, 2010.
[2]	Winter, M.L. Basic clinical pharmacokinetics. Philadelphia, Lippincott Williams & Wilkins, 2004.
[3]	DiPiro J.T et al. Pharmacotherapy A pathophysiologic approach, seven edition McGraw HILL, 2008.
[4]	Duhme D.W.,, Greenblatt D. J., Koch-Weser J. Reduction of digoxin toxicity associated with measurement of serum levels. A report from the Boston Collaborate Drug Surveillance Program. Ann Inter Med, 80: 516-519, 1974.
[5]	Dobbs R.J., Nicholson P.W., Dobbs S.M., O'Neill C.J. Therapeutic drug monitoring of digoxin: Helper or hinders?. Eur. J. clin. Pharmacol. 31:491-5, 1986.
[6]	Sidwell A., Barclay M., Begg E., Moore G. Digoxin therapeutic monitoring: an audit and review. The New Zeland Medical Journal, 116 (1187):1-6, 2003.
[7]	Farid S. F, Abbassia M.M, Sabrya N.A., Abdl Elkhaeq. Evaluation of digoxin in two Egyptian hospitals A pilot study. Austaralian Journal of basic and applied Sciences, 3(3):1838-1841, 2009.
[8]	Aronson J.K, Hardman M. ABC of monitoring drug therapy. Digoxin. BMJ, 305: 1149-52, 1992.
[9]	Kumana CR, Chan YM, Kou M. Audit exposes flawed blood sampling for “digoxin levels”. Ther Drug Monit, 14: 155-8, 1992.
[10]	Williamson KM, Thrasher KA, Fulton KB, et al. Digoxin toxicity: an evaluation in current clinical practice. Arch Intern Med, 158: 2444-9, 1998.
[11]	Smith TW, Haber E. Digoxin intoxication: the relationship of clinical presentation to serum digoxin concentration. J Clin Invest, 49: 2377-86, 1970.
[12]	Canas F, Tanasijevic MJ, Ma’luf N, Bates DW. Evaluating the appropriateness of digoxin level monitoring. Arch Intern Med, 159: 363-8, 1999.
[13]	Copeland RJ, Thorpe H, Kay EA. Inappropriate digoxin monitoring.J Clin Pharm Ther. 17:173-4, 1992.
[14]	Slaughter RL, Schneider PJ, Visconti JA. Appropriateness of the use of serum digoxin and digitoxin assays. Am J Hosp Pharm, 35: 1376-9. 1978.
[15]	Mordasini M.R., Krabenbublr S., Schlienger R. G. Appropriateness of digoxin level monitoring. SWISS MED WKLY, 132: 506-512, 2002.
[16]	Orrico K. B., Wu. M., Wilson A. R. Assessment of the appropriateness of serum digoxin concentration measurement in a medical group setting. Journal of Managed Care Pharmacy, 17(9): 695-700.2011.
[17]	Jessup M., Abraham WT., Casy DE, et al 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation, 119: 1977-2016. 2009.
[18]	Nagaraja N.V, Park Y.J, Jeon S, Sands C.D, Derendorf H. Population pharmacokinetics of digoxin in Korean patients. Int J Clin Pharmacol Ther. 38(6):291-7, 2000.
[19]	Zhou X.D, Gao Y, Guan Z, Li ZD, Li J. Population pharmacokinetic model of digoxin in older Chinese patients and its application in clinical practice. Acta Pharmacol Sin., 31(6):753-8, 2010.
[20]	Xiao-dan Zhou, Yan Gao, Zheng Guan, Zhong-dong Li and Jun Li. Population pharmacokinetic model of digoxin in older Chinese patients and its application in clinical practice. Acta Pharmacologica Sinica, 31: 753-758. 2010.
[21]	EL Desoky, E.S. Nagaraja, Nelamangala V.2; Derendorf, Hartmut. Population Pharmacokinetics of Digoxin in Egyptian Pediatric Patients: Impact of One Data Point Utilization. American Journal of Therapeutics: 9(6), 492-498. 2002.
[22]	Yukawa, E., Suematu, F.; Yukawa, M., Minemoto, M., Ohdo, S., Higuchi, S., Goto, Y., Aoyama, T. Population Pharmacokinetics of Digoxin in Japanese Patients: A 2-Compartment Pharmacokinetic Model. Clinical Pharmacokinetics, 40 (10), 773-781. 2001.
[23]	Cockcroft, D. & Gault, M., Prediction of creatinine clearance from serum creatinine. Nephron. 16, 31-41. 1976.
[24]	Ansel, H. & Prince, S. Pharmaceutical calculations: the pharmacist’s handbook. 1st Ed. United States of America: Lippincott Williams & Wilkins, 2004.
[25]	Bauer, L.A., Applied Clinical Pharmacokinetics. 1st Ed. United States of America: McGraw-Hill Professional. 2001.
[26]	Hornestam, B. & Karlsson, M., Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial. Eur J Clin Pharmacol 58.P.PP. 747-755, 2003.
[27]	Liu, D., Stay Healthy, Live Longer, Spend Wisely: Making Intelligent Choices inAmerica’s Healthcare System. 1st Ed. United States of America: Stetho Publishing, 2008.
[28]	Fong, B., Fong, A.C.M. & Li, C.K., Telemedicine Technologies: Information Technologies in Medicine and Telehealth. 1st Ed. india: John Wiley and Sons, 2011.
[29]	Goroll, A. & Mulley, A., Primary Care Medicine: Office EvaluationAnd Management of The AdultPatient. 6th Ed. china: Lippincott Williams & Wilkins‏. 2009.
[30]	Ford, S.M. & Roach, S.S., Roach’s Introductory Clinical Pharmacology. 9th Ed. London: Lippincott Williams & Wilkins. 2009.
[31]	Burke, M., Wilkes, G. & Ingwersen, K., Cancer Chemotherapy: a nursing process approach. 3rd Ed. United States of America: Jones & Bartlett Learning, 2001.
[32]	Ferrari, S.J., Bestetti, R.B., Cardinalli-neto, A. & Bortoluzzi, T.B., Article / Artigo Digoxin serum levels in patients with Chagas ’ cardiomyopathy and heart failure Níveis séricos de digoxina em pacientes com insuficiência cardíaca secundária à cardiomiopatia da doença de Chagas. Revista da Sociedade Brasileira de Medicina Tropical. 43 (5). 496-499. 2010.
[33]	Rich, M.W., McSherry, F., Williford, W.O. & Yusuf, S., Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. Journal of the American College of Cardiology. 38 (3). 806-13. 2001.
[34]	Baylis, E.M., Hall, M.S., Lewis, G. & Marks, V., Effects of renal function on plasma digoxin levels in elderly ambulant patients in domiciliary practice. British medical journal. 1 (5796). 338-41. 1972.
[35]	Abernethy, D., Greenblatt, D. & Smith, T. (1981a). Digoxin disposition in obesity: Clinical pharmacokinetic investigation. American Heart Journal. 102, 740-744. 1981.
[36]	Hosenpud, J.D. & Greenberg, B.H., Congestive Heart Failure. 3rd Ed. United States of America: Lippincott Williams & Wilkins, 2007.